MCD, Centre de Biologie Integrative (CBI), University of Toulouse, CNRS, UPS, 31062 Toulouse, France.
Institut de Génétique Humaine, CNRS, Université de Montpellier, Montpellier, France.
Biol Open. 2021 May 15;10(5). doi: 10.1242/bio.057729. Epub 2021 May 26.
KDM5A and KDM5B histone-demethylases are overexpressed in many cancers and have been involved in drug tolerance. Here, we describe that KDM5A, together with KDM5B, contribute to replication stress (RS) response and tolerance. First, they positively regulate RRM2, the regulatory subunit of ribonucleotide reductase. Second, they are required for optimal levels of activated Chk1, a major player of the intra-S phase checkpoint that protects cells from RS. We also found that KDM5A is enriched at ongoing replication forks and associates with both PCNA and Chk1. Because RRM2 is a major determinant of replication stress tolerance, we developed cells resistant to HU, and show that KDM5A/B proteins are required for both RRM2 overexpression and tolerance to HU. Altogether, our results indicate that KDM5A/B are major players of RS management. They also show that drugs targeting the enzymatic activity of KDM5 proteins may not affect all cancer-related consequences of KDM5A/B overexpression.
KDM5A 和 KDM5B 组蛋白去甲基酶在许多癌症中过表达,并与药物耐受性有关。在这里,我们描述了 KDM5A 和 KDM5B 共同参与复制应激(RS)反应和耐受性。首先,它们正向调节核糖核苷酸还原酶的调节亚基 RRM2。其次,它们是激活 Chk1 的最佳水平所必需的,Chk1 是保护细胞免受 RS 影响的内 S 期检查点的主要参与者。我们还发现 KDM5A 富集在正在进行的复制叉上,并与 PCNA 和 Chk1 相关联。由于 RRM2 是复制应激耐受的主要决定因素,我们开发了对 HU 有抗性的细胞,并表明 KDM5A/B 蛋白对于 RRM2 的过表达和对 HU 的耐受性都是必需的。总之,我们的研究结果表明 KDM5A/B 是 RS 管理的主要参与者。它们还表明,针对 KDM5 蛋白酶活性的药物可能不会影响 KDM5A/B 过表达的所有与癌症相关的后果。